hermo Fisher Scientific Inc. (NYSE: TMO) has acquired Proxeon A/S, an innovative supplier of
products for proteomics analysis headquartered in Odense, Denmark. The company is recognized for its ability to provide a simplified proteomics workflow, including nanoflow liquid chromatography systems, columns, ion sources, and bioinformatics software, to meet the need for robust high-sensitivity liquid chromatography/mass spectrometry (LC/MS) analysis in complex proteomics applications. Proxeon had revenues of approximately $10 million in 2009 and has nearly 40 employees. Proxeon‘s nanoflow liquid chromatography system, EASY-nLC, has been ad- opted by a number of the world‘s leading proteomic centers for its exceptional simplicity and ease of use. It features an intuitive graphical user interface, touch- screen operation and remote diagnostics capability.
Furthermore, TMO announced that its board of directors has authorized a one-year program to re- purchase $750 million of shares of its own common stock in the open market or in negotiated transac- tions. TMO has given notice of its intention to re- deem all of the outstanding Floating Rate Convertible Senior Debentures due 2033 (the „2033 Convertible Notes“).
As of April 20, 2010, $174,117,000 in aggregate principal amount of 2033 Convertible Notes is out- standing. In accordance with the terms of the inden- ture governing the 2033 Convertible Notes, they will be redeemed on May 10, 2010 (the „Redemption Date“) at a price of 100% of their principal amount, plus accrued and unpaid interest, including contin- gent interest to, but excluding, the Redemption Date. The 2033 Convertible Notes are convertible at any time prior to May 6, 2010 (the date that is two
business days prior to the Redemption Date), at a rate of 33.8409 shares of common stock per $1,000 principal amount of the 2033 Convertible Notes sur- rendered. The 2033 Convertible Notes surrendered for conversion will be settled in cash in accordance with the provisions of the indenture.
The Bank of New York Mellon, the trustee for the 2033 Convertible Notes, is mailing a Notice of Redemption to all registered holders of the 2033 Convertible Notes today. Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2033 Convertible Notes may be obtained from The Bank of New York Mellon by calling 800-254- 2826.
ransEnterix Inc. announce that surgeons at hospitals across the United States now are trea-
ting patients with the company’s proprietary SPIDER® Surgical System – which stands for Single Port Instru- ment Delivery Extended Reach. It is a single-port, multi-channel laparoscopic surgical platform and allows surgeons to perform minimally invasive abdo- minal surgeries entirely through a single port. In October 2009, TransEnterix secured $55 million in Series B financing, which will allow the company to manufacture and market its revolutionary SPIDER® Surgical System.
TransEnterix was founded in 2006 by Synecor, LLC, a business accelerator based in Durham, N.C., that creates highly disruptive technologies in the largest medical device and combination drug-device mar- kets. TransEnterix partners with the world’s leading physicians to develop pioneering technologies that
10-04 :: April 2010